Nanobiotix Sa - Adr (NBTX)

$5.5

+0.12

(+2.23%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Nanobiotix Sa - Adr

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.72M → 1.64M (in $), with an average decrease of 4.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -30.68M → -14.04M (in $), with an average increase of 118.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 10.5%

Performance

  • $5.31
    $5.50
    $5.50
    downward going graph

    3.45%

    Downside

    Day's Volatility :3.45%

    Upside

    0.0%

    downward going graph
  • $1.75
    $11.00
    $5.50
    downward going graph

    68.18%

    Downside

    52 Weeks Volatility :84.09%

    Upside

    50.0%

    downward going graph

Returns

PeriodNanobiotix Sa - AdrSector (Health Care)Index (Russel 2000)
3 Months
-30.94%
-0.7%
0.0%
6 Months
-17.23%
6.6%
0.0%
1 Year
43.85%
3.7%
-1.5%
3 Years
-62.85%
14.0%
-21.8%

Highlights

Market Capitalization
268.1M
Book Value
- $1.53
Earnings Per Share (EPS)
-1.79
Wall Street Target Price
11.91
Profit Margin
0.0%
Operating Margin TTM
-770.6%
Return On Assets TTM
-47.69%
Return On Equity TTM
-198.69%
Revenue TTM
6.7M
Revenue Per Share TTM
0.19
Quarterly Revenue Growth YOY
147.8%
Gross Profit TTM
4.8M
EBITDA
-46.1M
Diluted Eps TTM
-1.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Nanobiotix Sa - Adr(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 116.55%

Current $5.50
Target $11.91

Company Financials

FY17Y/Y Change
Revenue
252.0K
↓ 83.83%
Net Income
-26.1M
↑ 19.48%
Net Profit Margin
-10.4K%
↓ 8971.31%
FY18Y/Y Change
Revenue
132.7K
↓ 53.96%
Net Income
-34.2M
↑ 14.35%
Net Profit Margin
-25.8K%
↓ 15396.79%
FY19Y/Y Change
Revenue
76.2K
↓ 41.38%
Net Income
-57.0M
↑ 70.31%
Net Profit Margin
-74.9K%
↓ 49102.59%
FY20Y/Y Change
Revenue
61.5K
↓ 26.47%
Net Income
-41.4M
↓ 33.96%
Net Profit Margin
-67.2K%
↑ 7629.0%
FY21Y/Y Change
Revenue
11.3K
↓ 80.0%
Net Income
-53.2M
↑ 39.8%
Net Profit Margin
-470.0K%
↓ 402794.0%
FY22Y/Y Change
Revenue
5.1M
↑ 47660.0%
Net Income
-61.1M
↑ 21.36%
Net Profit Margin
-1.2K%
↑ 468845.63%
Q2 FY22Q/Q Change
Revenue
694.2K
-
Net Income
-27.5M
-
Net Profit Margin
-4.0K%
-
Q3 FY22Q/Q Change
Revenue
1.7M
↑ 159.37%
Net Income
-15.1M
↓ 41.79%
Net Profit Margin
-890.17%
↑ 3076.27%
Q1 FY23Q/Q Change
Revenue
1.9M
-
Net Income
-33.5M
-
Net Profit Margin
-1.8K%
-
Q2 FY23Q/Q Change
Revenue
1.8M
↓ 4.47%
Net Income
-15.3M
↓ 54.21%
Net Profit Margin
-853.29%
↑ 927.04%
FY17Y/Y Change
Total Assets
57.5M
↑ 89.02%
Total Liabilities
13.5M
↑ 4.15%
FY18Y/Y Change
Total Assets
52.8M
↓ 19.61%
Total Liabilities
36.6M
↑ 135.9%
FY19Y/Y Change
Total Assets
63.0M
↑ 21.67%
Total Liabilities
65.1M
↑ 81.88%
FY20Y/Y Change
Total Assets
164.9M
↑ 138.47%
Total Liabilities
78.2M
↑ 9.37%
FY21Y/Y Change
Total Assets
115.3M
↓ 24.07%
Total Liabilities
84.9M
↑ 17.96%
FY22Y/Y Change
Total Assets
64.0M
↓ 41.27%
Total Liabilities
93.0M
↑ 15.78%
Q1 FY22Q/Q Change
Total Assets
113.6M
↑ 0.0%
Total Liabilities
83.7M
↑ 0.0%
Q2 FY22Q/Q Change
Total Assets
84.2M
↓ 20.78%
Total Liabilities
82.4M
↑ 5.14%
Q3 FY22Q/Q Change
Total Assets
58.8M
↓ 25.87%
Total Liabilities
85.3M
↑ 10.13%
Q4 FY22Q/Q Change
Total Assets
64.0M
↑ 0.0%
Total Liabilities
93.0M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
65.2M
↑ 0.0%
Total Liabilities
94.7M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
44.1M
↓ 32.39%
Total Liabilities
102.8M
↑ 8.5%
FY17Y/Y Change
Operating Cash Flow
-21.0M
↑ 15.04%
Investing Cash Flow
-1.6M
↑ 251.25%
Financing Cash Flow
48.5M
↑ 111.98%
FY18Y/Y Change
Operating Cash Flow
-29.7M
↑ 23.55%
Investing Cash Flow
81.2K
↓ 104.54%
Financing Cash Flow
17.0M
↓ 69.4%
FY19Y/Y Change
Operating Cash Flow
-46.1M
↑ 58.43%
Investing Cash Flow
-1.6M
↓ 2154.93%
Financing Cash Flow
46.5M
↑ 179.39%
FY20Y/Y Change
Operating Cash Flow
-33.9M
↓ 33.11%
Investing Cash Flow
-137.8K
↓ 92.32%
Financing Cash Flow
137.5M
↑ 169.39%
FY21Y/Y Change
Operating Cash Flow
-33.8M
↑ 8.48%
Investing Cash Flow
-274.1K
↑ 116.07%
Financing Cash Flow
-5.9M
↓ 104.63%
FY22Y/Y Change
Operating Cash Flow
-39.7M
↑ 24.21%
Investing Cash Flow
147.8K
↓ 157.02%
Financing Cash Flow
-6.1M
↑ 9.09%
Q1 FY22Q/Q Change
Operating Cash Flow
-9.8M
↑ 18.36%
Investing Cash Flow
29.6K
↓ 127.6%
Financing Cash Flow
-2.0M
↑ 0.83%
Q2 FY22Q/Q Change
Operating Cash Flow
-18.7M
↑ 104.1%
Investing Cash Flow
27.7K
↑ 0.0%
Financing Cash Flow
-3.3M
↑ 79.52%
Q3 FY22Q/Q Change
Operating Cash Flow
-9.6M
↓ 45.22%
Investing Cash Flow
41.8K
↑ 60.38%
Financing Cash Flow
-1.1M
↓ 65.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.5M
↑ 0.0%
Investing Cash Flow
45.5K
↑ 0.0%
Financing Cash Flow
-1.1M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.0M
↑ 105.68%
Investing Cash Flow
-178.3K
↓ 484.71%
Financing Cash Flow
-1.7M
↑ 48.16%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.4M
↓ 57.12%
Investing Cash Flow
-178.4K
↑ 0.0%
Financing Cash Flow
-1.2M
↓ 32.72%

Technicals Summary

Sell

Neutral

Buy

Nanobiotix Sa - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nanobiotix Sa - Adr
Nanobiotix Sa - Adr
-14.33%
-17.23%
43.85%
-62.85%
-62.85%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nanobiotix Sa - Adr
Nanobiotix Sa - Adr
NA
NA
NA
0.0
-1.99
-0.48
NA
-1.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nanobiotix Sa - Adr
Nanobiotix Sa - Adr
Buy
$268.1M
-62.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Johnson & Johnson

    11.94%

  • Baillie Gifford & Co Limited.

    6.09%

  • Perceptive Advisors LLC

    1.18%

  • BlackRock Inc

    0.46%

  • UBS Group AG

    0.01%

Corporate Announcements

  • Nanobiotix Sa - Adr Earnings

    Nanobiotix Sa - Adr’s price-to-earnings ratio stands at None

    Read More

Company Information

nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea

Organization
Nanobiotix Sa - Adr
Employees
101
CEO
Mr. Laurent Levy Ph.D.
Industry
Healthcare

Discover More

FAQs